RSM logo
JRSM

Home Current issue Browse archive Alerts About the journal Feedback
 
J R Soc Med 1989;82:458-461
© 1989 Royal Society of Medicine

This Article
Right arrow Send a Quick Comment
Right arrow Alert me when this article is cited
Right arrow Alert me when Quick Comments are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tharakan, J.
Right arrow Articles by Smith, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of the Royal Society of Medicine, Vol 82, Issue 8 458-461, Copyright © 1989 by Royal Society of Medicine

ORIGINAL ARTICLES

Plasma exchange for Guillain-Barre syndrome

J Tharakan, RE Ferner, RA Hughes, J Winer, M Barnett, ER Brown and G Smith
Department of Neurology, United Medical and Dental School Guy's Hospital, London.

The impact of plasma exchange (PE) on the treatment of severe Guillain-Barre syndrome (GBS) was studied by comparing all the 16 patients treated with PE in a London teaching hospital between January 1985 and August 1987, with 64 historical controls drawn from a series of patients observed during a prospective study in South East England in 1983 and 1984. There were no GBS-related deaths in the PE treated group but seven in the historical controls (2P = 0.39). The median duration of ventilation was only 20 days (range 7-64) in the PE group compared with 36 days (range 14-365) in the surviving patients in the control group (2P = 0.06, 95% confidence interval of difference in medians -36 to 0 days). The PE group walked earlier without aid (median 55.5 compared with 86 days, 2P = 0.04, 95% confidence interval of difference in medians -88 to -2 days). Three months after the onset of neuropathy all PE treated patients were able to walk with support or better, whereas 19 of the surviving historical controls were unable to walk even with support (2P = 0.009). The costs of PE were offset by savings in intensive care unit and hospital expenditure.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
R.A.C. Hughes, E.F.M. Wijdicks, R. Barohn, E. Benson, D.R. Cornblath, A. F. Hahn, J.M. Meythaler, R.G. Miller, J.T. Sladky, and J.C. Stevens
Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology, September 23, 2003; 61(6): 736 - 740.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J H Rees, R D Thompson, N C Smeeton, and R A C Hughes
Epidemiological study of Guillain-Barre syndrome in south east England
J. Neurol. Neurosurg. Psychiatry, January 1, 1998; 64(1): 74 - 77.
[Abstract] [Full Text]


MDU Exam Doctor

 RSM Journals - Obstetric Medicine International Journal of Care Pathways